Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Aquarius Biotechnologies, Inc. (Details)

v2.4.1.9
Acquisition of Aquarius Biotechnologies, Inc. (Details) (Aquarius Biotechnologies, Inc. [Member], USD $)
 1 Months Ended
Jan. 29, 2015
Aquarius Biotechnologies, Inc. [Member]
  
Business Acquisition [Line Items]  
Fair value of 4,608,020 of common stock issued at a price per share of $0.46 as of January 29, 2015the closing date of the merger. $ 2,119,689us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future clinical milestone 422,609mtnb_BusinessCombinationContingentConsiderationUponAchievingCertainFutureClinicalMilestone
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember 		[1]
Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future regulatory milestone 330,737mtnb_BusinessCombinationContingentConsiderationUponAchievingCertainFutureRegulatoryMilestone
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember 		[1]
Total consideration $ 2,873,035us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
[1] Reflects recognition of the estimated fair value of the contingent consideration payable with issuance of Matinas common stock upon achievement of certain future clinical and regulatory milestones, the achievement of which is uncertain.